Artiva Biotherapeutics (ARTV) Leases (2023 - 2025)
Historic Leases for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $11.3 million.
- Artiva Biotherapeutics' Leases fell 2166.11% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year decrease of 2166.11%. This contributed to the annual value of $13.8 million for FY2024, which is 1663.75% down from last year.
- According to the latest figures from Q3 2025, Artiva Biotherapeutics' Leases is $11.3 million, which was down 2166.11% from $12.7 million recorded in Q2 2025.
- Artiva Biotherapeutics' 5-year Leases high stood at $16.5 million for Q4 2023, and its period low was $11.3 million during Q3 2025.
- Its 3-year average for Leases is $13.9 million, with a median of $13.8 million in 2024.
- The largest annual percentage gain for Artiva Biotherapeutics' Leases in the last 5 years was 1599.58% (2025), contrasted with its biggest fall of 2166.11% (2025).
- Artiva Biotherapeutics' Leases (Quarter) stood at $16.5 million in 2023, then dropped by 16.64% to $13.8 million in 2024, then fell by 18.36% to $11.3 million in 2025.
- Its Leases stands at $11.3 million for Q3 2025, versus $12.7 million for Q2 2025 and $13.5 million for Q1 2025.